MedTrace Logo

Pharmacokinetic Study to Determine Time to Steady-state

NCT00911586 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2020-12-11

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to confirm how long (i.e., how many days) it takes to reach steady-state when testosterone undecanoate is administered twice daily.

Conditions

  • Male Hypogonadism
  • Primary Hypogonadism
  • Secondary Hypogonadism

Interventions

DRUG

Testosterone undecanoate

Sponsors & Collaborators

  • Clarus Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Gregory Flippo, MD · Alabama Clinical Therapeutics

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-07-31
Primary Completion
2009-09-30
Completion
2010-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00911586 on ClinicalTrials.gov